As House Republicans moved closer Wednesday to agreement on a bill to repeal Obamacare, top UPMC officials in Pittsburgh laid out how and why they expect the region’s largest health care system to thrive regardless of what happens in Washington, D.C.
“We think we have the elements of success for the future,” said Robert DeMichiei, UPMC’s chief financial officer.
That optimism comes from the synergy — scientific and financial — of having a hospital system, health plan and major medical school operating collaboratively, UPMC officials said.
UPMC now ranks fifth nationally for the number of National Institutes of Health grants received, behind Harvard, the University of Pennsylvania, Johns Hopkins University and the University of California-San Francisco.
The more than $500 million in NIH grants coming to Pitt fuels the school’s research, teaching and training, which leads to more patient referrals and improved clinical quality in the health system.
In addition, UPMC last year contributed $405 million to Pitt’s Schools of Health Sciences for research and education.
The blueprint for success in this area hearkens back to the arrival of late organ transplant pioneer Thomas Starzl in the early 1980s and the center’s subsequent rise to international medical prominence, said Art Levine, dean of the University of Pittsburgh School of Medicine. “That has marked the culture of UPMC ever since.”
The addition of the UPMC Health Plan to its organizational chart also plays an important role.
While hospitals traditionally have been paid based on the amount of care they provide, the movement now is toward value and providing quality care for lower cost.
Now, said Mr. DeMichiei, “We can make money by doing less” because premium dollars from 3.2 million health plan members offset lost revenue from fewer hospital stays.
For the quarter ending March 31, UPMC saw a slight drop in after-tax operating income, from $73 million in 2016 to $71.6 million for the first three months of 2017.
Patient revenue went up year-over-year, from $1.48 billion in 2016 to just under $1.7 billion this year.
Over the first nine months of its current fiscal year that ends June 30, UPMC saw its operating margin drop to 1.7 percent, compared with 2.8 percent a year ago when it had benefited from an arbitration ruling following a dispute with Highmark over chemotherapy payments.
The deliberations in Washington could send ripples through the entire health care system nationally, particularly if proposed Medicaid funding means more low-income families will lose their health coverage.
And if discussions on cutting NIH funding next year become reality, cutting into research, everyone may feel the impact eventually, said Mr. DeMichiei.
“If this investment goes away, then those [medical] breakthroughs go away.”
Steve Twedt: stwedt@post-gazette.com or 412-263-1963.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.